Indeed, the European Research Initiative on CLL (ERIC) group recommends TP53 mutational screening for all patients before the start of therapy to avoid a treatment that may be ineffective for patients carrying TP53 mutations [10]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.